5-苄氧基烟酸 | 263270-34-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 5-苄氧基烟酸
• 英文名称: 5-(benzyloxy)nicotinic acid
• 英文别名: 5-phenylmethoxypyridine-3-carboxylic acid
• CAS: 263270-34-4
• 化学式: C₁₃H₁₁NO₃
• 分子量: 229.235
• InChiKey: MWWYJDHPRJSMBL-UHFFFAOYSA-N

物化性质

• 沸点：
  436.0±30.0 °C(Predicted)
• 密度：
  1.274±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  59.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-苄氧基烟酸 在 三乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 26.0h， 生成 (5-(benzyloxy)pyridin-3-yl)(cyclopropyl)methanone
  参考文献：
  名称：

  [EN] CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES
  [FR] AGONISTES CYCLOHEXYLE DE GPR40 POUR LE TRAITEMENT DU DIABÈTE DE TYPE 2

  摘要：

  披露了用于治疗受GPR40受体调节影响的疾病的化合物、组合物和方法。这类化合物由公式(I)表示，如下所示：(公式(I))，其中R1、R2、R3、A、W、L、Ra和G在本文中定义；以及由公式(II)表示，如下所示：(公式(II))，其中R1B、WB、LB和GB在本文中定义。

  公开号：

  WO2018081047A1
• 作为产物：
  描述：

  5-羟基-3-吡啶羧酸乙酯 在 水 、 三苯基膦 、 lithium hydroxide 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 0.01h， 生成 5-苄氧基烟酸
  参考文献：
  名称：

  [EN] CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES
  [FR] AGONISTES CYCLOHEXYLE DE GPR40 POUR LE TRAITEMENT DU DIABÈTE DE TYPE 2

  摘要：

  披露了用于治疗受GPR40受体调节影响的疾病的化合物、组合物和方法。这类化合物由公式(I)表示，如下所示：(公式(I))，其中R1、R2、R3、A、W、L、Ra和G在本文中定义；以及由公式(II)表示，如下所示：(公式(II))，其中R1B、WB、LB和GB在本文中定义。

  公开号：

  WO2018081047A1

文献信息

• 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND
  申请人：Kuribayashi Takeshi

  公开号：US20110112103A1

  公开（公告）日：2011-05-12

  The present invention provides compounds which promote erythropoietin production. Compounds represented by the following general formula (1) or pharmacologically acceptable salts thereof are provided: [wherein, R 1 represents a group —X-Q 1 , X-Q 1 -Y-Q 2 or X-Q 1 -Y-Q 2 -Z-Q 3 , X represents a single bond, —CH 2 — or the like, Q 1 represents a monocyclic or bicyclic heterocyclic group which may have substituent(s), Y represents a single bond, —CH 2 —, or the like, Q 2 represents a monocyclic or bicyclic hydrocarbon ring group which may have substituent(s) or a monocyclic or bicyclic heterocyclic group which may have substituent(s), Z represents a single bond, —CR 11 R 12 — or the like, R 11 and R 12 each independently represents a hydrogen atom, a halogen atom or the like, Q 3 represents a phenyl group which may have substituent(s), a C 3 -C 7 cycloalkyl group which may have substituent(s), a C 3 -C 7 cycloalkenyl group which may have substituent(s) or a monocyclic or bicyclic heterocyclic group which may have substituent(s), R 2 represents a C 1 -C 3 alkyl group or the like, and R 3 represents a hydrogen atom or a methyl group].

  本发明提供促进促红细胞生成素产生的化合物。提供以下一般式（1）表示的化合物或其药理学上可接受的盐： [其中，R 1 表示一个基团-X-Q 1 ，X-Q 1 -Y-Q 2 或X-Q 1 -Y-Q 2 -Z-Q 3 ，X表示一个单键，-CH 2 -或类似物，Q 1 表示可能具有取代基的单环或双环杂环基团，Y表示一个单键，-CH 2 -或类似物，Q 2 表示可能具有取代基的单环或双环碳氢环基团或可能具有取代基的单环或双环杂环基团，Z表示一个单键，-CR 11 R 12 -或类似物，R 11 和R 12 各自独立地表示氢原子、卤素原子或类似物，Q 3 表示可能具有取代基的苯基团，可能具有取代基的C 3 -C 7 环烷基团，可能具有取代基的C 3 -C 7 环烯基团或可能具有取代基的单环或双环杂环基团，R 2 表示C 1 -C 3 烷基团或类似物，R 3 表示氢原子或甲基基团]。
• Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors
  申请人：Mjalli M.M. Adnan

  公开号：US20060223849A1

  公开（公告）日：2006-10-05

  The present invention is directed to benzazole compounds that inhibit β-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment or prevention of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which BACE is involved.

  本发明涉及一种抑制β-淀粉样前体蛋白剪切酶（BACE）的苯并咪唑化合物，该化合物可用于治疗或预防BACE参与的疾病，如阿尔茨海默病。本发明还涉及包含这些化合物的药物组合物以及在预防或治疗BACE参与的这些疾病中使用这些化合物和组合物的用途。
• Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors
  申请人：Mjalli Adnan M.M.

  公开号：US20090326006A1

  公开（公告）日：2009-12-31

  The present invention is directed to benzazole compounds that inhibit β-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment or prevention of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which BACE is involved.

  本发明涉及抑制β位点淀粉样前体蛋白剪切酶（BACE）的苯并唑化合物，可用于治疗或预防BACE参与的疾病，如阿尔茨海默病。本发明还涉及包含这些化合物的药物组合物，以及在预防或治疗BACE参与的这些疾病中使用这些化合物和组合物的用途。
• Benzazole Derivatives, Compositions, and Methods of Use as B-Secretase Inhibitors
  申请人：Mjalli Adnan M.M.

  公开号：US20110065713A1

  公开（公告）日：2011-03-17

  The present invention is directed to benzazole compounds that inhibit β-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment or prevention of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which BACE is involved.

  本发明涉及一种抑制 β-淀粉样前体蛋白裂解酶（BACE）的苯并咪唑化合物，该化合物可能在治疗或预防包括阿尔茨海默病在内的与BACE有关的疾病中有用。本发明还涉及包含这些化合物的药物组合物以及在预防或治疗BACE参与的这类疾病中使用这些化合物和组合物。
• Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors
  申请人：High Point Pharmaceuticals, LLC

  公开号：US07893267B2

  公开（公告）日：2011-02-22

  The present invention is directed to benzazole compounds that inhibit β-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment or prevention of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which BACE is involved.

  本发明涉及一种抑制β-淀粉样前体蛋白裂解酶（BACE）的苯并咪唑化合物，可用于治疗或预防BACE参与的疾病，如阿尔茨海默病。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗BACE参与的这些疾病中使用这些化合物和组合物。